Beta-adrenergic blockade in patients with myocardial infarction: Evolution, efficacy and controversy

Ezra A Amsterdam, Shahad Al Chalaby, Sean Fraser, Naveen Gupta, Tina Gupta, Muhammad Majid, Balasingam Thevakumar, Navya Sree Vipparla, Sandhya Venugopal

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Beta-adrenergic blockade was launched into the treatment of cardiovascular disease over half a century ago. The unique effects of these drugs in reducing myocardial oxygen demand, by attenuating heart rate, blood pressure, and myocardial contractility and their antiarrhythmic actions, conferred major benefits in conditions such as angina, hypertension and arrhythmias. During the pre-coronary reperfusion era, large randomized trials with β-blockers in patients with acute myocardial infarction revealed significant reductions in morbidity and mortality in the early and late phases of the disease. However, with the application of new therapeutic approaches including coronary reperfusion, hemodynamic assessment, and an increasing array of new drugs (antiplatelet agents, inhibitors of the renin-angiotensin-aldosterone axis) utilized in myocardial infarction patients, the efficacy of β-blockade in reducing mortality and complications appeared to be less than in earlier studies. For the past four decades, numerous investigations have addressed this question with resultant mixed answers, which are attributable to the variable study cohorts, specific β-blocker, dosage, associated therapy, and length of follow-up. At present, oral β-blockers are recommended (class I) in guidelines for management of patients with acute myocardial infarction. Intravenous β- blockade is restricted to consideration for patients with no hemodynamic dysfunction or risk factors for this complication. The β-blockers recommended in patients with infarction are carvedilol, metoprolol succinate, or bisoprolol, each of which is associated with decreased mortality in patients with heart failure.

Original languageEnglish (US)
Title of host publicationBeta-Blockers
Subtitle of host publicationPhysiological, Pharmacological and Therapeutic Implications
PublisherNova Science Publishers, Inc.
Pages273-285
Number of pages13
ISBN (Electronic)9781536133127
ISBN (Print)9781536133110
StatePublished - Jan 1 2018

Fingerprint

Adrenergic Agents
Myocardial Infarction
Myocardial Reperfusion
Mortality
Hemodynamics
Bisoprolol
Metoprolol
Platelet Aggregation Inhibitors
Angiotensins
Aldosterone
Renin
Pharmaceutical Preparations
Infarction
Cardiac Arrhythmias
Cohort Studies
Cardiovascular Diseases
Therapeutics
Heart Failure
Heart Rate
Guidelines

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Amsterdam, E. A., Al Chalaby, S., Fraser, S., Gupta, N., Gupta, T., Majid, M., ... Venugopal, S. (2018). Beta-adrenergic blockade in patients with myocardial infarction: Evolution, efficacy and controversy. In Beta-Blockers: Physiological, Pharmacological and Therapeutic Implications (pp. 273-285). Nova Science Publishers, Inc..

Beta-adrenergic blockade in patients with myocardial infarction : Evolution, efficacy and controversy. / Amsterdam, Ezra A; Al Chalaby, Shahad; Fraser, Sean; Gupta, Naveen; Gupta, Tina; Majid, Muhammad; Thevakumar, Balasingam; Vipparla, Navya Sree; Venugopal, Sandhya.

Beta-Blockers: Physiological, Pharmacological and Therapeutic Implications. Nova Science Publishers, Inc., 2018. p. 273-285.

Research output: Chapter in Book/Report/Conference proceedingChapter

Amsterdam, EA, Al Chalaby, S, Fraser, S, Gupta, N, Gupta, T, Majid, M, Thevakumar, B, Vipparla, NS & Venugopal, S 2018, Beta-adrenergic blockade in patients with myocardial infarction: Evolution, efficacy and controversy. in Beta-Blockers: Physiological, Pharmacological and Therapeutic Implications. Nova Science Publishers, Inc., pp. 273-285.
Amsterdam EA, Al Chalaby S, Fraser S, Gupta N, Gupta T, Majid M et al. Beta-adrenergic blockade in patients with myocardial infarction: Evolution, efficacy and controversy. In Beta-Blockers: Physiological, Pharmacological and Therapeutic Implications. Nova Science Publishers, Inc. 2018. p. 273-285
Amsterdam, Ezra A ; Al Chalaby, Shahad ; Fraser, Sean ; Gupta, Naveen ; Gupta, Tina ; Majid, Muhammad ; Thevakumar, Balasingam ; Vipparla, Navya Sree ; Venugopal, Sandhya. / Beta-adrenergic blockade in patients with myocardial infarction : Evolution, efficacy and controversy. Beta-Blockers: Physiological, Pharmacological and Therapeutic Implications. Nova Science Publishers, Inc., 2018. pp. 273-285
@inbook{07ffc8640df048df9d025b5f9e1a3eb3,
title = "Beta-adrenergic blockade in patients with myocardial infarction: Evolution, efficacy and controversy",
abstract = "Beta-adrenergic blockade was launched into the treatment of cardiovascular disease over half a century ago. The unique effects of these drugs in reducing myocardial oxygen demand, by attenuating heart rate, blood pressure, and myocardial contractility and their antiarrhythmic actions, conferred major benefits in conditions such as angina, hypertension and arrhythmias. During the pre-coronary reperfusion era, large randomized trials with β-blockers in patients with acute myocardial infarction revealed significant reductions in morbidity and mortality in the early and late phases of the disease. However, with the application of new therapeutic approaches including coronary reperfusion, hemodynamic assessment, and an increasing array of new drugs (antiplatelet agents, inhibitors of the renin-angiotensin-aldosterone axis) utilized in myocardial infarction patients, the efficacy of β-blockade in reducing mortality and complications appeared to be less than in earlier studies. For the past four decades, numerous investigations have addressed this question with resultant mixed answers, which are attributable to the variable study cohorts, specific β-blocker, dosage, associated therapy, and length of follow-up. At present, oral β-blockers are recommended (class I) in guidelines for management of patients with acute myocardial infarction. Intravenous β- blockade is restricted to consideration for patients with no hemodynamic dysfunction or risk factors for this complication. The β-blockers recommended in patients with infarction are carvedilol, metoprolol succinate, or bisoprolol, each of which is associated with decreased mortality in patients with heart failure.",
author = "Amsterdam, {Ezra A} and {Al Chalaby}, Shahad and Sean Fraser and Naveen Gupta and Tina Gupta and Muhammad Majid and Balasingam Thevakumar and Vipparla, {Navya Sree} and Sandhya Venugopal",
year = "2018",
month = "1",
day = "1",
language = "English (US)",
isbn = "9781536133110",
pages = "273--285",
booktitle = "Beta-Blockers",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Beta-adrenergic blockade in patients with myocardial infarction

T2 - Evolution, efficacy and controversy

AU - Amsterdam, Ezra A

AU - Al Chalaby, Shahad

AU - Fraser, Sean

AU - Gupta, Naveen

AU - Gupta, Tina

AU - Majid, Muhammad

AU - Thevakumar, Balasingam

AU - Vipparla, Navya Sree

AU - Venugopal, Sandhya

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Beta-adrenergic blockade was launched into the treatment of cardiovascular disease over half a century ago. The unique effects of these drugs in reducing myocardial oxygen demand, by attenuating heart rate, blood pressure, and myocardial contractility and their antiarrhythmic actions, conferred major benefits in conditions such as angina, hypertension and arrhythmias. During the pre-coronary reperfusion era, large randomized trials with β-blockers in patients with acute myocardial infarction revealed significant reductions in morbidity and mortality in the early and late phases of the disease. However, with the application of new therapeutic approaches including coronary reperfusion, hemodynamic assessment, and an increasing array of new drugs (antiplatelet agents, inhibitors of the renin-angiotensin-aldosterone axis) utilized in myocardial infarction patients, the efficacy of β-blockade in reducing mortality and complications appeared to be less than in earlier studies. For the past four decades, numerous investigations have addressed this question with resultant mixed answers, which are attributable to the variable study cohorts, specific β-blocker, dosage, associated therapy, and length of follow-up. At present, oral β-blockers are recommended (class I) in guidelines for management of patients with acute myocardial infarction. Intravenous β- blockade is restricted to consideration for patients with no hemodynamic dysfunction or risk factors for this complication. The β-blockers recommended in patients with infarction are carvedilol, metoprolol succinate, or bisoprolol, each of which is associated with decreased mortality in patients with heart failure.

AB - Beta-adrenergic blockade was launched into the treatment of cardiovascular disease over half a century ago. The unique effects of these drugs in reducing myocardial oxygen demand, by attenuating heart rate, blood pressure, and myocardial contractility and their antiarrhythmic actions, conferred major benefits in conditions such as angina, hypertension and arrhythmias. During the pre-coronary reperfusion era, large randomized trials with β-blockers in patients with acute myocardial infarction revealed significant reductions in morbidity and mortality in the early and late phases of the disease. However, with the application of new therapeutic approaches including coronary reperfusion, hemodynamic assessment, and an increasing array of new drugs (antiplatelet agents, inhibitors of the renin-angiotensin-aldosterone axis) utilized in myocardial infarction patients, the efficacy of β-blockade in reducing mortality and complications appeared to be less than in earlier studies. For the past four decades, numerous investigations have addressed this question with resultant mixed answers, which are attributable to the variable study cohorts, specific β-blocker, dosage, associated therapy, and length of follow-up. At present, oral β-blockers are recommended (class I) in guidelines for management of patients with acute myocardial infarction. Intravenous β- blockade is restricted to consideration for patients with no hemodynamic dysfunction or risk factors for this complication. The β-blockers recommended in patients with infarction are carvedilol, metoprolol succinate, or bisoprolol, each of which is associated with decreased mortality in patients with heart failure.

UR - http://www.scopus.com/inward/record.url?scp=85048451940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048451940&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:85048451940

SN - 9781536133110

SP - 273

EP - 285

BT - Beta-Blockers

PB - Nova Science Publishers, Inc.

ER -